BRPI1013626B8 - método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico - Google Patents

método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico

Info

Publication number
BRPI1013626B8
BRPI1013626B8 BRPI1013626A BRPI1013626A BRPI1013626B8 BR PI1013626 B8 BRPI1013626 B8 BR PI1013626B8 BR PI1013626 A BRPI1013626 A BR PI1013626A BR PI1013626 A BRPI1013626 A BR PI1013626A BR PI1013626 B8 BRPI1013626 B8 BR PI1013626B8
Authority
BR
Brazil
Prior art keywords
physiologically active
active polypeptide
polypeptide conjugate
specific
preparing site
Prior art date
Application number
BRPI1013626A
Other languages
English (en)
Inventor
Hae Song Dae
Sun Lee Gwan
Hee Shin Jae
Min Lee Jae
Chang Kwon Se
Kyung Park Young
Original Assignee
Hanmi Holdings Co Ltd
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co Ltd, Hanmi Science Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of BRPI1013626A2 publication Critical patent/BRPI1013626A2/pt
Publication of BRPI1013626B1 publication Critical patent/BRPI1013626B1/pt
Publication of BRPI1013626B8 publication Critical patent/BRPI1013626B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

método para preparar conjugado de polipeptídeo flslologicamente ativo em sítio específico. a presente invenção provê um método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico com alto rendimento, pelo tratamento de um poiipeptídeo fisiologicamente ativo com um polímero não peptídico na presença de um álcool em um ph especifico, o qual pode ser desejavelmente empregado no desenvolvimento de formulações de ação prolongada de vários fármacos peptídicos com alta atividade in vivo e meia-vida no sangue acentuadamente prolongada.
BRPI1013626A 2009-03-20 2010-03-18 método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico BRPI1013626B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20090023953 2009-03-20
KR10-2009-0023953 2009-03-20
PCT/KR2010/001674 WO2010107256A2 (en) 2009-03-20 2010-03-18 Method for preparing a site-specific physiologically active polypeptide conjugate

Publications (3)

Publication Number Publication Date
BRPI1013626A2 BRPI1013626A2 (pt) 2016-04-19
BRPI1013626B1 BRPI1013626B1 (pt) 2021-05-11
BRPI1013626B8 true BRPI1013626B8 (pt) 2021-05-25

Family

ID=42740133

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013626A BRPI1013626B8 (pt) 2009-03-20 2010-03-18 método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico

Country Status (24)

Country Link
US (1) US8895281B2 (pt)
EP (1) EP2408800B1 (pt)
JP (2) JP5759976B2 (pt)
KR (1) KR101164453B1 (pt)
CN (1) CN102369209B (pt)
AR (1) AR075913A1 (pt)
AU (1) AU2010225523B2 (pt)
BR (1) BRPI1013626B8 (pt)
CA (1) CA2755395C (pt)
DK (1) DK2408800T3 (pt)
ES (1) ES2587397T3 (pt)
HR (1) HRP20161055T1 (pt)
HU (1) HUE030373T2 (pt)
IL (1) IL215165A (pt)
MX (1) MX2011009803A (pt)
MY (1) MY150536A (pt)
NZ (1) NZ595848A (pt)
PL (1) PL2408800T3 (pt)
PT (1) PT2408800T (pt)
RU (1) RU2495881C2 (pt)
SG (1) SG174320A1 (pt)
TW (1) TWI472342B (pt)
WO (1) WO2010107256A2 (pt)
ZA (1) ZA201107658B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101511660B1 (ko) * 2010-10-08 2015-04-13 고쿠리츠 다이가쿠 호진 교토 다이가쿠 펩티드 유도체 및 그 사용
US9278146B2 (en) 2010-10-08 2016-03-08 Kyoto University Peptide derivative and use of the same
CN102675452B (zh) * 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
CN106928341B (zh) * 2011-03-30 2021-06-01 上海仁会生物制药股份有限公司 定点单取代聚乙二醇化Exendin类似物及其制备方法
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
KR102092206B1 (ko) * 2011-06-02 2020-03-24 옵코 바이오로직스 리미티드 장기-작용성 glp-1/글루카곤 수용체 작용제
UA126465C2 (uk) * 2011-06-10 2022-10-12 Ханмі Сайенс Ко., Лтд. Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
RU2607365C2 (ru) * 2011-06-17 2017-01-10 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
EA201492269A1 (ru) 2012-06-04 2016-02-29 Опко Байолоджикс Лтд. Пегилированные варианты oxm
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
WO2014073842A1 (en) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR20140088837A (ko) * 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
MX361083B (es) * 2013-02-26 2018-11-27 Hanmi Pharma Co Ltd Conjugado de insulina específico de sitio.
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
CN103804483A (zh) * 2014-03-13 2014-05-21 中国人民解放军第四军医大学 Orexin-A聚乙二醇化修饰物及其制备方法
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
US11123436B2 (en) 2015-07-24 2021-09-21 Hanmi Pharm. Co., Ltd. Method of preparing physiologically active polypeptide conjugate
WO2017052329A1 (en) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
KR101974305B1 (ko) * 2018-02-14 2019-04-30 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
CN109678930B (zh) * 2018-12-05 2022-04-29 西北工业大学 聚乙二醇修饰的npff及其用途
CN109535244B (zh) * 2018-12-11 2020-12-01 上海景峰制药有限公司 一种重组人脑利钠肽的纯化方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204726A1 (en) * 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
CA2372214A1 (en) 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
CA2422707A1 (en) * 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US8423976B2 (en) * 2003-03-13 2013-04-16 Northrop Grumman Corporation Extreme pipeline and optimized reordering technology
JP2006520818A (ja) * 2003-03-19 2006-09-14 イーライ リリー アンド カンパニー ポリエチレングリコール結合ｇｌｐ−１化合物
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
DK2599502T3 (en) * 2003-04-11 2017-04-18 Antriabio Inc Process for Preparation of Site-Specific Protein Conjugates
BRPI0413644A (pt) 2003-08-21 2006-10-17 Novo Nordisk As métodos para separar as duas formas de um polipeptìdeo tendo uma única racemização de aminoácido, e para separar dois polipeptìdeos, produto de polipeptìdeo, e, composição farmacêutica
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体

Also Published As

Publication number Publication date
PL2408800T3 (pl) 2016-11-30
JP5759976B2 (ja) 2015-08-05
CN102369209B (zh) 2015-06-10
US8895281B2 (en) 2014-11-25
TWI472342B (zh) 2015-02-11
ZA201107658B (en) 2012-12-27
MY150536A (en) 2014-01-30
TW201036640A (en) 2010-10-16
WO2010107256A2 (en) 2010-09-23
CA2755395C (en) 2015-02-24
KR101164453B1 (ko) 2012-07-11
IL215165A0 (en) 2011-12-29
IL215165A (en) 2016-11-30
PT2408800T (pt) 2016-08-23
JP2015127330A (ja) 2015-07-09
HK1163120A1 (en) 2012-09-07
DK2408800T3 (en) 2016-08-29
EP2408800A4 (en) 2012-12-05
AR075913A1 (es) 2011-05-04
MX2011009803A (es) 2011-09-30
ES2587397T3 (es) 2016-10-24
SG174320A1 (en) 2011-10-28
JP2012520873A (ja) 2012-09-10
EP2408800B1 (en) 2016-05-25
AU2010225523A1 (en) 2011-11-10
US20120003712A1 (en) 2012-01-05
EP2408800A2 (en) 2012-01-25
HUE030373T2 (en) 2017-05-29
CN102369209A (zh) 2012-03-07
HRP20161055T1 (hr) 2016-11-04
BRPI1013626A2 (pt) 2016-04-19
RU2495881C2 (ru) 2013-10-20
KR20100105494A (ko) 2010-09-29
WO2010107256A3 (en) 2011-03-17
AU2010225523B2 (en) 2012-05-24
RU2011142332A (ru) 2013-04-27
NZ595848A (en) 2014-04-30
BRPI1013626B1 (pt) 2021-05-11
CA2755395A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
BRPI1013626B8 (pt) método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico
Bodineau et al. Two parallel pathways connect glutamine metabolism and mTORC1 activity to regulate glutamoptosis
Adams et al. Centrosome amplification mediates small extracellular vesicle secretion via lysosome disruption
Brown et al. Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer
Karvela et al. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells
BRPI1012141A2 (pt) conjugado de sirna e método de preparação do mesmo
MY152304A (en) An insulin conjugate using an immunoglobulin fragment
Ross et al. Histone-targeted polyplexes avoid endosomal escape and enter the nucleus during postmitotic redistribution of ER membranes
AR069328A1 (es) Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad
ECSP088962A (es) Nuevos herbicidas
Orellana et al. Enhancing microRNA activity through increased endosomal release mediated by nigericin
BR112012008142A2 (pt) conjugados de peptídeo/ polietilenoglicol liga dos a dissulfeto para a transfecção de ácidos nucleicos
Ratelade et al. Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica
CY1118373T1 (el) Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος
BR112014010818A2 (pt) método para preparar complexo de polipeptídeo fisiologicamente ativo
Stansley et al. Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus
WO2010036918A3 (en) Intracellular dna receptor
AR063150A1 (es) Formulaciones estables
AR077901A1 (es) Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer
DE602005011753D1 (de) Pharmazeutische zusammensetzungen mit midazolam in hoher konzentration
FR2933773B1 (fr) Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
Fortian et al. Endocytosis of ubiquitylation‐deficient EGFR mutants via clathrin‐coated pits is mediated by ubiquitylation
EA201400539A1 (ru) Введение ингибитора фермента, активирующего nedd8, и гипометилирующего средства
MX2015000686A (es) Metodo para detectar cancer.
Cho et al. A tumor-homing peptide platform enhances drug solubility, improves blood–brain barrier permeability and targets glioblastoma

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B25G Requested change of headquarter approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF